[Form 4] Bankunited, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Citadel-related entities and Kenneth Griffin have disclosed a near-10% passive stake in MEI Pharma (MEIP). A Schedule 13G filed for the 22 Jul 2025 event shows aggregate beneficial ownership of 3,245,888 common shares, equal to 9.99 % of the 32,491,374 shares outstanding.

• Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC jointly own 3,167,695 shares (9.75%) with shared voting and dispositive power.
• Citadel Securities-affiliated vehicles hold 78,193 shares (0.24%).
• Stake size includes 2,084,509 shares issued and 527,110 shares still issuable from the voluntary exercise or conversion of warrants; each warrant is subject to a 9.99 % ownership cap.
• The filing is on Schedule 13G, indicating the position is passive; the certification explicitly states there is no intent to influence control of MEIP.
• All reporting persons share a business address: 830 Brickell Plaza, Miami, FL.

The disclosure introduces a high-profile institutional holder but does not signal an activist agenda or immediate strategic change for MEI Pharma.

Positive

• High-profile institutional ownership: Citadel and Kenneth Griffin now hold 9.99 % of MEIP, potentially supporting liquidity and investor confidence.

Negative

• Incremental dilution: 2.08 m shares were issued and another 0.53 m are still issuable from warrant conversions tied to Citadel’s stake, modestly increasing the share count.

Insights

Equity Analyst

TL;DR: Large passive stake by Citadel adds liquidity support but no control intent—impact modest.

Citadel’s 9.99 % ownership elevates institutional participation in MEIP, potentially improving trading liquidity and market visibility. Because the position is filed under Schedule 13G—not 13D—and includes a certification of passivity, the probability of governance intervention appears low. The stake derives partly from warrant exercises, which incrementally increased the share count, but the resulting dilution is already reflected in the 32.5 m share base cited. Overall, this is a neutral-to-mildly positive signal: a respected hedge fund has validated MEIP’s valuation yet remains below the 10 % threshold that would trigger additional reporting requirements.

Corporate Governance Specialist

TL;DR: Position capped below 10 %; no activism flags—governance risk unchanged.

The joint filing consolidates seven Citadel entities plus Kenneth Griffin, clarifying control relationships and preventing fragmented disclosures. Shared voting power on all 3.25 m shares means Griffin can influence outcomes if desired, but the 13G certification and lack of sole voting authority mitigate takeover concerns. The warrant cap also limits future ownership beyond 9.99 %, reducing the chance of stealth accumulation. For boards and investors, governance posture remains status-quo; monitoring is advisable but no immediate defensive action is required.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

PAULS DOUGLAS J

(Last) (First) (Middle)

C/O BANKUNITED, INC.

14817 OAK LANE

(Street)

MIAMI LAKES FL 33016

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BankUnited, Inc. [ BKU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.01 per share	07/25/2025		S		3,500(1)	D	$38.79	43,205	D
Common Stock, par value $0.01 per share								31,000	I	As Co-Trustee(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the sale of 3,500 shares of common stock by the reporting person under Rule 144 promulgated under the Securities Act of 1933, as amended.

2. Shares held by the Pauls Family Foundation, for which Mr. Pauls serves as a co-trustee. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein and the inclusion of these share in this report shall not be deemed an admission of beneficial ownership of these shares for Section 16 or for any other purpose.

	/s/ Jacqueline Bravo, as Attorney-in-Fact	07/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MEI Pharma shares does Citadel own according to the 2025 Schedule 13G?

Citadel-managed entities beneficially own 3,167,695 shares, equal to 9.75 % of outstanding stock.

What is Kenneth Griffin’s total ownership in MEIP?

Including all affiliated vehicles, Kenneth Griffin is deemed to beneficially own 3,245,888 shares (9.99 %).

Is the Citadel position activist or passive?

The filing is on Schedule 13G; the certification states the shares are not held to change or influence control, indicating a passive stake.

Did the stake involve new share issuance?

Yes. The position includes 2,084,509 shares issued and 527,110 shares still issuable from the voluntary exercise or conversion of warrants.

What is the CUSIP for MEI Pharma common stock?

The CUSIP disclosed in the filing is 55279B301.